Vertex (VRTX) Q1 2026 earnings review
Stable CF Growth Masks a High-Stakes Pivot
Vertex delivered stable 8% YoY revenue growth to $2.99B, driven by the massive, ongoing transition of its cystic fibrosis (CF) patient base from TRIKAFTA to ALYFTREK. However, the real story is Vertex's high-stakes pivot to a multi-franchise company. While the non-CF products (CASGEVY and JOURNAVX) are growing, they contributed just $71.9M in 26Q1. With management reiterating full-year non-CF guidance of '$500 million or more', they are banking on a massive acceleration in the back half of the year. Non-GAAP Net Income grew a stable 9% to $1.15B, though operating expenses surged as the company builds out its commercial footprint for JOURNAVX and clinical trials for its emerging renal franchise.
🐂 Bull Case
The rapid cannibalization of TRIKAFTA by ALYFTREK ($424M in 26Q1) effectively resets Vertex's CF patent clock to 2039 and lowers their royalty burden, securing the foundational cash cow for another decade.
With inclusion in the Medicare NOPAIN Act (retroactive to Jan 2026) and a new Medicare Part D agreement covering 10 million lives, JOURNAVX is overcoming its primary gross-to-net and access headwinds.
🐻 Bear Case
At just $72M in combined Q1 revenue, CASGEVY and JOURNAVX are currently tracking far below the >$500M full-year target, implying the company needs significant and flawless acceleration in the remaining three quarters.
The termination of the VX-522 mRNA program leaves the remaining ~5,000 CF patients who cannot tolerate modulators without a clear near-term pipeline solution.
⚖️ Verdict: ⚪
Neutral. The underlying CF business remains an absolute fortress, but the valuation premium demands success in the non-CF launches. Q1 data shows progress, but the math required to hit the 2026 non-CF guidance leaves little room for error.
Key Themes
ALYFTREK Cannibalization is Accelerating
The transition from TRIKAFTA to ALYFTREK is the primary driver in the CF segment. ALYFTREK revenue surged from $54M a year ago to $424M in 26Q1, while TRIKAFTA revenue declined sequentially and YoY to $2.35B. This is exactly what management wants: migrating the base to a superior, once-daily regimen with better intellectual property protection.
JOURNAVX Institutional and Payer Wins
JOURNAVX revenue remains small ($29M) but shows stable sequential growth. Crucially, the structural blockers to adoption are being cleared: CMS approved its inclusion in the NOPAIN Act separate payment list (retroactive to Jan 23), and Medicare Part D coverage was secured for 10M lives starting May 1. Over 240M individuals now have reimbursed access, setting the stage for accelerating revenue.
Povetacicept Regulatory Advancement
The 'fourth vertical' renal franchise is moving at lightspeed. Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy for U.S. accelerated approval and is utilizing a Priority Review Voucher to shorten the FDA review to six months. Furthermore, they initiated the Phase 3 portion of the study in primary membranous nephropathy.
VX-522 mRNA Program Terminated
A reversing trend in technological innovation: Vertex officially ended the Phase 1/2 study of VX-522 (its partnered nebulized CFTR mRNA therapy) due to persistent tolerability issues. This represents a definitive failure to capture the final ~5,000 CF patients who cannot benefit from small-molecule correctors, leaving a gap in the company's otherwise complete dominance of the disease.
CASGEVY Quarter-to-Quarter Variability
CASGEVY revenue decelerated sequentially, dropping to $43M in 26Q1 from $54M in 25Q4. The long, complex patient journey from referral to cell collection to infusion continues to create lumpy revenue recognition. While expected, this variability makes it difficult to project a smooth acceleration curve for the gene therapy.
The Math on Non-CF Guidance
Vertex is maintaining its guidance of 'greater than $500M' in non-CF revenue for FY26. However, 26Q1 delivered only $71.9M. To hit the $500M target, the remaining three quarters must average ~$143M each. This represents a steep, demanding ramp that leaves the company highly vulnerable to minor commercialization hiccups.
Resilience to Macro Tariff Pressures
In a nod to the current macro-political environment, management explicitly noted that their 2026 expense guidance includes an 'immaterial cost impact from tariffs based on currently known tariff rates and regulations.' This confirms previous commentary that the company's diverse supply chain effectively shields it from significant geopolitical supply disruptions.
Elevated R&D and Commercial Spend
Operating expenses continue to swell. Combined GAAP R&D and SG&A expenses rose to $1.5B and $1.3B respectively. Management attributes this directly to commercial investments supporting the JOURNAVX launch and the build-out of the renal franchise (povetacicept). The non-GAAP effective tax rate also rose to 19.6% from 18.8%.
Other KPIs
Accelerating slightly from $12.3 billion at the end of 2025. The balance sheet remains a fortress, with cash generation from operations easily funding heavy R&D investments, commercial buildouts, and ongoing share repurchase programs.
Reversing the optical weakness of the prior year. Q1 2026 GAAP Net Income surged compared to the $646 million reported in Q1 2025, primarily because the year-ago quarter contained a massive $379 million intangible asset impairment charge related to a discontinued Type 1 Diabetes program.
Guidance
Stable. Guidance is completely unchanged from the prior quarter, implying roughly 8-9% YoY growth from FY25's $12.0 billion. Given the heavy reliance on CF, this represents high-confidence, highly visible recurring revenue.
Accelerating implied growth. With only $72M achieved in Q1, achieving this target requires CASGEVY and JOURNAVX to double their average quarterly run rate over the rest of the year. Relies heavily on the newly secured CMS and Part D access for JOURNAVX.
Stable compared to prior guidance, representing a significant YoY step-up from FY25's ~$5.1 billion. The difference reflects the aggressive expansion of the sales force for JOURNAVX and the expensive late-stage clinical trials for povetacicept and the pain portfolio.
Key Questions
VX-522 Replacement Strategy
With the termination of the VX-522 mRNA program due to tolerability issues, what is the updated strategic roadmap for treating the final ~5,000 CF patients, and does this permanently cede that portion of the market to potential competitors?
Bridging the Non-CF Revenue Gap
With only $72M of non-CF revenue recognized in Q1, what specific leading indicators (such as early NOPAIN Act adoption or scheduled CASGEVY infusions) give you confidence in hitting the heavily back-loaded $500M+ full-year target?
JOURNAVX Gross-to-Net Normalization
Given the recent wins with Medicare Part D and NOPAIN Act inclusion, how rapidly do you expect the elevated gross-to-net discounts associated with patient support programs to normalize throughout 2026?